Literature DB >> 15931729

Hope for AD with NGF gene-therapy trial.

Jane Bradbury.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15931729     DOI: 10.1016/s1474-4422(05)70086-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  5 in total

Review 1.  Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.

Authors:  Christian Hölscher
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 6.497

Review 2.  New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases.

Authors:  Christian Hölscher
Journal:  Neural Regen Res       Date:  2014-11-01       Impact factor: 5.135

3.  The novel adamantane derivatives as potential mediators of inflammation and neural plasticity in diabetes mice with cognitive impairment.

Authors:  Iwona Piątkowska-Chmiel; Monika Gawrońska-Grzywacz; Łukasz Popiołek; Mariola Herbet; Jarosław Dudka
Journal:  Sci Rep       Date:  2022-04-25       Impact factor: 4.996

Review 4.  Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseases.

Authors:  Christian Hölscher
Journal:  Front Synaptic Neurosci       Date:  2022-07-27

5.  Over-expression of hNGF in adult human olfactory bulb neural stem cells promotes cell growth and oligodendrocytic differentiation.

Authors:  Hany E S Marei; Asmaa Althani; Nahla Afifi; Ahmed Abd-Elmaksoud; Camilla Bernardini; Fabrizio Michetti; Marta Barba; Mario Pescatori; Giulio Maira; Emanuela Paldino; Luigi Manni; Patrizia Casalbore; Carlo Cenciarelli
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.